Bloomberg TV

Novavax CEO Erck Says Covid-19 Mutation Wouldn’t Affect Vaccine

Jul.07 — Novavax Chief Executive Officer Stan Erck discusses the company’s progress on developing a Covid-19 vaccine, the $1.6 billion contribution to the effort from the U.S. government’s Operation Warp Speed program, and global inoculation production capacity. He speaks on "Bloomberg Markets: European Close."